Results 191 to 200 of about 677,734 (335)

Enhanced plasma half-life and efficacy of engineered human albumin-fused GLP-1 despite enzymatic cleavage of its C-terminal end. [PDF]

open access: yesCommun Biol
Nilsen J   +10 more
europepmc   +1 more source

Illustration

open access: yesRevista Argentina de Cardiología, 2012
openaire   +1 more source

Dosimetric evaluation and clinical application of collimated apertures with proton beam line scanning in stereotactic radiotherapy

open access: yesJournal of Applied Clinical Medical Physics, EarlyView.
Abstract Purpose Stereotactic radiotherapy (SRT) is a highly effective treatment with precision for small, localized lesions. Proton therapy, characterized by the Bragg peak, offers superior dose conformity compared to photon‐based approaches. However, challenges remain in minimizing lateral penumbra and optimizing dose delivery, particularly for small
Chen‐Yu Chou   +3 more
wiley   +1 more source

Radiotherapy medical physics in the Philippines: A contemporary overview

open access: yesJournal of Applied Clinical Medical Physics, EarlyView.
Abstract Purpose With cancer ranking as the third leading cause of death in the Philippines and a disparity in healthcare resources across regions, this research aimed to assess the state of radiotherapy medical physics in the country. Methodology The study utilized a comprehensive online survey with 94 structured questions answered by 19 clinics ...
John Paul C. Cabahug   +4 more
wiley   +1 more source

Localization accuracy of 6‐second CBCT for lung IGRT with various breathing patterns

open access: yesJournal of Applied Clinical Medical Physics, EarlyView.
Abstract Purpose The 6‐second cone beam computed tomography (CBCT) acquisition of the Ethos HyperSight (Varian Medical Systems, Inc. Palo Alto, CA, USA) on‐board imaging system offers benefits, but could be too fast to accurately capture an average target position in a free‐breathing lung cancer patient. This study aimed to ascertain whether a 6‐second
Jihye Koo   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy